ImmunityBio Q4 net product revenue $7.2M; Feb ANKTIVA units up 67% MoM; RMAT designation granted

ImmunityBio, Inc.

Net product revenue $7.2M in Q4 2024, up 21% QoQ from $6.0M in Q3; full-year net product revenue $14.2M.
ANKTIVA February 2025 unit sales up 67% month-over-month from January; Jan+Feb combined exceed total Q4 2024 units.
Permanent J-code (J9028) issued Jan 2025; FDA authorized expanded access of rBCG with over 45,000 vials available and 60+ sites activating.
MAAs for ANKTIVA+BCG accepted by MHRA and EMA in Feb 2025; RMAT designation for ANKTIVA+PD-L1 t-haNK in pancreatic cancer.
Net loss attributable to common stockholders narrowed to $59.2M in Q4 2024 from $233.4M in Q4 2023; cash and securities $149.8M at Dec 31.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.